EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

16 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

06 Nov 2024 16:49:03 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Third Quarter 2024 Financial Results

06 Nov 2024 16:05:01 By Nasdaq GlobeNewswire

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

04 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

23 Oct 2024 07:30:55 By Nasdaq GlobeNewswire

Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

08 Oct 2024 17:32:28 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility

02 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

26 Sep 2024 08:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

25 Sep 2024 07:07:16 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

13 Sep 2024 06:45:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

12 Sep 2024 08:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile

03 Sep 2024 07:08:45 By Nasdaq GlobeNewswire

Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness

30 Aug 2024 08:16:09 By Nasdaq GlobeNewswire

Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

29 Aug 2024 18:53:02 By Nasdaq GlobeNewswire

Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals

20 Aug 2024 11:30:55 By Nasdaq GlobeNewswire

Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa

19 Aug 2024 17:10:37 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Second Quarter 2024 Financial Results

06 Aug 2024 17:01:01 By Nasdaq GlobeNewswire

Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country

06 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million

31 Jul 2024 08:53:06 By Nasdaq GlobeNewswire

NetDania - New 12 months High: EMERGENT BIOSOLUTIONS INC. COMMON STOCK

30 Jul 2024 09:46:26 By NetDania Notify